Grant v. Csl Behring LLC

District Court, District of Columbia·Decided March 31, 2023·No. Civil Action No. 2021-2044·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

JULIA GRANT, Plaintiff,

v. Civil Action No. 1:21-cv-02044 (CJN)

CSL BEHRING, LLC, Defendant.

MEMORANDUM OPINION

In March 2021, biopharmaceutical company CSL Behring, LLC terminated the employment of Julia Grant, who then initiated this lawsuit for discrimination and retaliation under the D.C. Human Rights Act. CSL has moved for summary judgment on all claims, arguing that Grant’s termination was not motivated by unlawful discrimination or retaliation, but by a company reorganization. Grant maintains that this stated reason is pretextual. For the reasons explained below, the Court grants summary judgment to CSL on Grant’s retaliation claim, but denies summary judgment on her age and sex discrimination claims.

I. Background

CSL is a biopharmaceutical company that “researches, develops, manufactures, and markets plasma protein biotherapies . . . used to treat serious and rare medical conditions.”1 Def.’s Statement of Facts (“Def.’s SOMF”) ¶ 1, ECF No. 24. On May 1, 2017, CSL hired Grant as Director of U.S. Healthcare Policy and Federal Affairs (or more simply, “Director of Federal

1 Unless otherwise noted, these facts are undisputed or established by uncontroverted evidence, at least at the summary judgment stage.

Government Affairs”). Id. ¶ 2. Grant remained in that position throughout the entirety of her employment with the company. Id. ¶ 3. Her job duties included “forging relationships” in Washington, D.C., “to help advance CSL’s position in policy” on matters that concerned the company, like patient access or new biopharmaceutical products. Def.’s Ex. C (Wixted Corp. Tr.) at 28; see Def.’s SOMF ¶ 18 (describing Grant’s role as “focusing on the legislative process and driving advocacy initiatives within Congress”).

Grant’s direct supervisor during the entirety of her employment at CSL was Patrick Collins, whose title was Senior Director of Global Healthcare Policy and External Affairs. Def.’s SOMF ¶ 6. Michael Ruggiero joined the company in June 2019 as the Senior Vice President of Global Healthcare Policy and External Affairs; among other things, Ruggiero was Collins’s superior. Id. ¶ 7; Def.’s Ex. C (Wixted Corp. Tr.) at 23. Ruggiero was tasked with “review[ing] the organization and prepar[ing] it for the future.” Def.’s Ex. F (Ruggiero Tr.) at 46–47. In other words, he assessed the structure of the organization and considered how to improve it. See id. at 45. Although the global government affairs function of CSL also had teams covering policy matters in other parts of the world, the reorganization as relevant here concerned only the group focused on North American affairs.

As it stood when Ruggiero joined, the North America government affairs group consisted of six employees subordinate to him. Collins (again, Senior Director of Global Healthcare Policy and External Affairs) reported to Ruggiero and supervised both Grant (again, Director of Federal Government Affairs) and Karla White (Director of State Government Affairs). See Def.’s Ex. G (Org. Charts) at 3361. White had three direct reports, and Grant had none. Pl.’s Statement of Facts (“Pl.’s SOMF”) ¶¶ 59–60, ECF No. 25; Def.’s Resp. to Pl.’s SOMF (“Def.’s Resp.”)

¶¶ 59–60, ECF No. 26-2. Grant’s office was located in Washington, D.C., while Collins was based in Pennsylvania. Pl.’s SOMF ¶ 4. A. Restructuring of the North America Government Affairs Group The Parties dispute how best to characterize the effect of Ruggiero’s reorganization. What is clear is that Ruggiero added an Executive Director-level position to lead the North America group (called the “Head of North America Healthcare Policy & External Affairs”), who would supervise a Senior Director of Federal Affairs and the existing Director of State Government Affairs. Def.’s SOMF ¶ 13; see Def.’s Ex. G (Org. Charts) at 3366. The Senior Director of Federal Affairs would have no direct reports, and the Director of State Government Affairs would have three. See Def.’s Ex. G (Org. Charts) at 3366. And key to this lawsuit, there would no longer be a Director of Federal Affairs—the position held by Grant. See id.; Def.’s SOMF ¶ 16.

According to CSL, pairing the new Executive Director with a Senior Director instead of a Director focused on federal affairs within the North America group would involve “sacrific[ing] the tactical execution of congressional strategy performed by a Director level role,” but the Senior Director would have the benefit of “a deep understanding of CSL’s business” when developing policy strategy. Def.’s SOMF ¶¶ 15–18. Outside consultants could fill the gap left by the loss of a Director-level role by executing the more “tactical elements” of advocacy work. Id. ¶¶ 16–17.

After Ruggiero first proposed a restructuring in approximately April 2020, he went on to produce multiple iterations of the reorganization plan over the course of the next several months. Id. ¶ 22; Def.’s Ex. E (CSL Interrog. Resps.) ¶ 8; see Pl.’s Ex. 1 (Wixted Corp. Tr.) at 225–28. One aspect of the initial plan, which lasted through many iterations, was to eliminate both Grant’s Director role and Collins’s Senior Director role, but then fill the position of Senior Director of Federal Affairs with a new hire. See Def.’s Ex. G (Org. Charts) at 3362, 3364; Pl.’s Ex. 1 (Wixted

Corp. Tr.) at 148–49. Having experienced a successful virtual working environment during the COVID-19 pandemic, however, CSL later decided that Collins could fill the Senior Director position—which was supposed to be based in Washington, D.C.—from his location in Pennsylvania. Def.’s SOMF ¶ 29. Ruggiero revised the plan to retain Collins in the Senior Director role, but the plan still involved terminating Grant. Id. ¶¶ 33–34. Ruggiero selected Mary-Lacey Reuther to fill the Executive Director role. Id. ¶¶ 35–36.

The way Grant sees it, the reorganization did not involve the creation of any new roles, but merely their renaming, as duties were shifted among members of the team. In Grant’s view, Reuther was placed in Collins’s position; Collins was placed in Grant’s position; and Grant was terminated. See Pl.’s Resp. to Def.’s SOMF (“Pl.’s Resp.”) ¶¶ 13, 33–35, ECF No. 25. B. CSL Investigation In early October 2020, Collins forwarded an email exchange to Grant and the Nickles Group, a political consulting firm, regarding the possibility of having then-First Lady Melania Trump donate convalescent plasma following her recovery from COVID-19 to publicly promote plasma donation. Def.’s SOMF ¶¶ 38–39; Def.’s Ex. B (Grant Tr.) at 69, 106; see Pl.’s SOMF ¶ 18. Grant replied to Collins and Ruggiero asking why she was not included in the original discussion about the idea. Def.’s SOMF ¶ 40. After receiving Grant’s reply, Collins called her and advised her to recall the email, but Grant informed Collins that she did not know how to recall emails and that she was “tired” of “being marginalized, cut out, [and] not included” by Collins and Ruggiero. Def.’s Ex. B (Grant Tr.) at 110; Pl.’s Ex. 4 (Collins Tr.) at 93–97. Grant also told Collins that she was “not afraid” of him and Ruggiero. Def.’s SOMF ¶ 41; Def.’s Ex. B (Grant Tr.) at 110–11. Collins understood from the exchange that Grant was raising a concern about CSL’s treatment of women. Def.’s SOMF ¶ 42.

Free access — add to your briefcase to read the full text and ask questions with AI

Grant v. Csl Behring LLC, (D.D.C. 2023).

Grant v. Csl Behring LLC (Grant v. Csl Behring LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Gaujacq v. EDF, Inc.
601 F.3d 565 (D.C. Circuit, 2010)
McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Stella, Marie v. v. Mineta, Norman Y.
284 F.3d 135 (D.C. Circuit, 2002)
Murray, Lucy v. Gilmore, David
406 F.3d 708 (D.C. Circuit, 2005)
Woodruff, Phillip v. Peters, Mary
482 F.3d 521 (D.C. Circuit, 2007)
Brady v. Office of the Sergeant at Arms
520 F.3d 490 (D.C. Circuit, 2008)
Taylor v. Solis
571 F.3d 1313 (D.C. Circuit, 2009)
Etim U. Aka v. Washington Hospital Center
156 F.3d 1284 (D.C. Circuit, 1998)
Reeves v. Sanderson Plumbing Products, Inc.
530 U.S. 133 (Supreme Court, 2000)
McFarland v. George Washington University
935 A.2d 337 (District of Columbia Court of Appeals, 2007)
Hollins v. Federal National Mortgage Ass'n
760 A.2d 563 (District of Columbia Court of Appeals, 2000)
Estenos v. PAHO/WHO Federal Credit Union
952 A.2d 878 (District of Columbia Court of Appeals, 2008)
Daka, Inc. v. Breiner
711 A.2d 86 (District of Columbia Court of Appeals, 1998)
Furline v. Morrison
953 A.2d 344 (District of Columbia Court of Appeals, 2008)
Cain v. REINOSO
43 A.3d 302 (District of Columbia Court of Appeals, 2012)
Brandli v. Micrus Endovascular Corporation
209 F. Supp. 3d 356 (District of Columbia, 2016)
Carpenter v. Federal National Mortgage Ass'n
174 F.3d 231 (D.C. Circuit, 1999)